ClinicalTrials.gg
CompletedNCT04004429BEGINUpdated Jul 10, 2024Results posted

A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease

A Phase 2 interventional study of 50 mg AP1189 and AP1189 in Rheumatoid Arthritis, sponsored by SynAct Pharma Aps. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by SynAct Pharma Aps · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Arthritis, Rheumatoid with a site in Denmark — 14 open to participants now, 23 under way, 2 of them phase 3. Arthritis, Rheumatoid · Denmark.

Enrollment
45th of 70
105 · median 160
Started
2019
with 2 others
Phase 2
10 of 99
3 open now
Registered
72nd of 99
by date

Among the 99 studies in Arthritis, Rheumatoid with a site in Denmark, this one is the 45th largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 2, and was the 72nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

14 of the 99 studies in Arthritis, Rheumatoid with a site in Denmark are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Arthritis, Rheumatoid with a site in Denmark, or all of them as a file.
02

Study summary

This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) > 22, who are to start up-titration with methotrexate.

Read the detailed description

A multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) > 22, who are to start up-titration with methotrexate.

The study will be conducted in two parts separated by an interim analysis.

Part 1: The subjects will be randomized in a 1:1:1 ratio into: .

  • AP1189 dose 50 mg
  • AP1189 dose 100 mg
  • placebo

INTERIM ANALYSIS

Part 2: All subjects will be randomized into either design 1, 2 or 3 based on data from the interim analysis.

  • Design 1: AP1189 dose 50 mg or placebo in a 2:1 ratio
  • Design 2: AP1189 dose 100 mg or placebo in a 2:1 ratio
  • Design 3: Continue with the same doses as in Part 1

The purpose of this study is to determine the safety and efficacy of 2 doses of AP1189 compared with placebo after 4 weeks of treatment.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Written has been obtained prior to initiating any study specific procedures
  • Male and female subjects, 18 to 85 years of age
  • Confirmed diagnosis of RA (Rheumatoid Arthritis) according to the 2010 American College of Rheumatology (ACR)/EULAR RA classification criteria
  • Polyarthritis with joint swelling and tenderness of a minimum of three joints out of 68 joints tested
  • Candidate for Methotrexate treatment
  • Is about to begin treatment with MTX (Methotrexate)
  • Tested positive for anti-CCP (Anti-cyclic citrullinated peptide) or RF (Rheumatoid Factor)
  • Severe active RA (Clinical Disease Activity Index (CDAI)) > 22) at screening and baseline
  • Negative QFG-IT (QuantiFERON-in-Tube test)
  • Subjects should be able to complete the PRO (Patient Reported Outcome) questionnaires
  • Females of may only participate if using reliable means of or are . Surgically sterilized women at least 6 months prior to screening
  • Females of childbearing potential must have a negative pregnancy test at screening and baseline

Exclusion Criteria:

  • Participation in any other study involving drug(s) within 4 weeks prior to study entry
  • Major surgery within 8 weeks prior to screening or planned surgery within 1 month following randomization
  • Rheumatic disease other than RA, including SLE (systemic Lupus Erythematosus), MCTD (Mixed Connective Tissue Disease), scleroderma, polymyositis, or significant systemic involvement secondary to RA. Sjögren syndrome with RA is allowable
  • Functional class IV as defined by the ACR Criteria for Classification of Functional Status in RA or wheelchair/bedbound
  • Prior history of or current inflammatory joint disease other than RA
  • Subjects with fibromyalgia
  • Initiation or change in dose for NSAIDs within 2 weeks prior to dosing with the IMP (Investigational Medicinal Product)
  • are prohibited within 2 weeks prior to screening (and during the entire treatment period and until the final visit
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
  • Have prior renal transplant, current renal dialysis or severe renal insufficiency (determined by a derived (GFR) using Formula of ≤30 mL/min/1,73 m2 calculated by the local lab)
  • Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
  • Evidence of active malignant disease
  • Pregnant women or nursing mothers
  • History of alcohol, drug, or chemical abuse within the 6 months prior to screening
  • Neuropathies or other painful conditions that might interfere with pain evaluation
  • Body weight of >150 kg

Exclusion criteria that only applies for Norway

  • Evidence of moderate and/or severe organ dysfunction
  • Abnormal chest x-ray (as per the discretion of the investigator
  • Evidence of positive hepatitis serology
  • Evidence of peptic ulcer disease
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    50 mg AP1189

    50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.

    Drug: 50 mg AP1189

  • Experimental
    100 mg AP1189

    100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.

    Drug: AP1189

  • Placebo comparator
    Placebo

    Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.

    Drug: Placebo

Interventions

  • 50 mg AP1189 powder in bottle

    Also known as: AP1189

  • DrugAP1189

    100 mg AP1189 powder in bottle

  • DrugPlacebo

    Placebo powder in bottle

06

What researchers measure

Primary outcomes

  1. Change in Clinical Disease Activity Index (CDAI)

    The change in CDAI from severe (CDAI \> 22) to moderate (CDAI \<= 22) after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity)

    Time frame: 4 weeks

  2. Change in Clinical Disease Activity Index (CDAI)

    The change in CDAI after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity). The CDAI score range is from 0 - 76, whereas a score of: ≤2.8 means Remission \>2.8 and ≤10 means Low Disease Activity \>10 and ≤22 means Moderate Disease Activity \>22 means High Disease Activity For the purpose of this study, a decrease in CDAI (improvement) is reported as - xx.xx).

    Time frame: 4 weeks

Secondary outcomes

  1. ACR (American College of Rheumatology) Response

    Proportion of subjects achieving a response assessed by ACR20. The ACR response rate ACR20 is defined as ≥20% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.

    Time frame: 4 weeks

  2. ACR (American College of Rheumatology) Response

    Proportion of subjects achieving a response assessed by ACR50. The ACR response rate ACR50 is defined as ≥50% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.

    Time frame: 4 weeks

  3. ACR (American College of Rheumatology) Response

    Proportion of subjects achieving a response assessed by ACR70. The ACR response rate ACR70 is defined as ≥70% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.

    Time frame: 4 weeks

07

Results

Posted Jul 10, 2024

Participant flow

Participant flow — Overall Study
Milestone50 mg AP1189100 mg AP1189Placebo
Started353634
Completed333432
Not completed222
Withdrew: Protocol violation100
Withdrew: Physician decision011
Withdrew: Withdrawal by subject111

Outcome measures

PrimaryChange in Clinical Disease Activity Index (CDAI)

The change in CDAI from severe (CDAI \> 22) to moderate (CDAI \<= 22) after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity)

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Change in Clinical Disease Activity Index (CDAI)
Participants50 mg AP1189100 mg AP1189Placebo
Change in Clinical Disease Activity Index (CDAI)181712
PrimaryChange in Clinical Disease Activity Index (CDAI)

The change in CDAI after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity). The CDAI score range is from 0 - 76, whereas a score of: ≤2.8 means Remission \>2.8 and ≤10 means Low Disease Activity \>10 and ≤22 means Moderate Disease Activity \>22 means High Disease Activity For the purpose of this study, a decrease in CDAI (improvement) is reported as - xx.xx).

Time frame:
4 weeks
Reported as:
Mean · Calculated score
Change in Clinical Disease Activity Index (CDAI)
Calculated score50 mg AP1189100 mg AP1189Placebo
Change in Clinical Disease Activity Index (CDAI)-11.97 ± 8.74-15.52 ± 12.70-9.33 ± 10.58
SecondaryACR (American College of Rheumatology) Response

Proportion of subjects achieving a response assessed by ACR20. The ACR response rate ACR20 is defined as ≥20% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
ACR (American College of Rheumatology) Response
Participants50 mg AP1189100 mg AP1189Placebo
ACR (American College of Rheumatology) Response112010
SecondaryACR (American College of Rheumatology) Response

Proportion of subjects achieving a response assessed by ACR50. The ACR response rate ACR50 is defined as ≥50% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
ACR (American College of Rheumatology) Response
Participants50 mg AP1189100 mg AP1189Placebo
ACR (American College of Rheumatology) Response284
SecondaryACR (American College of Rheumatology) Response

Proportion of subjects achieving a response assessed by ACR70. The ACR response rate ACR70 is defined as ≥70% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
ACR (American College of Rheumatology) Response
Participants50 mg AP1189100 mg AP1189Placebo
ACR (American College of Rheumatology) Response041

Adverse events

Collected over All Adverse Event (AE)s were collected starting from the time of signed informed consent and until the final visit (End of Study/Early Termination visit) had occurred. Any AE that was ongoing at the final visit was followed until resolution or until four weeks after the study drug administration, whichever came first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50 mg AP11890/35 (0%)0/35 (0%)14/35 (40%)
100 mg AP11890/36 (0%)0/36 (0%)16/36 (44.4%)
Placebo0/34 (0%)0/34 (0%)12/34 (35.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
Event50 mg AP1189100 mg AP1189Placebo
NauseaGastrointestinal disorders5/357/367/34
Alanine aminotransferase increasedInvestigations6/350/363/34
HeadacheNervous system disorders2/355/360/34
GGT increasedInvestigations3/350/363/34
Arthritis rheumatoid aggravatedMusculoskeletal and connective tissue disorders3/352/361/34
ConstipationGastrointestinal disorders2/353/360/34
Aspartate aminotransferase increasedInvestigations2/350/362/34
AnemiaBlood and lymphatic system disorders2/351/361/34
ObstipationGastrointestinal disorders2/351/360/34
DiarrheaInvestigations1/352/360/34

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)50 mg AP1189100 mg AP1189PlaceboTotal
<=18 years0000
Between 18 and 65 years25262576
>=65 years1010929
Sex: Female, Male
Sex: Female, Male(Participants)50 mg AP1189100 mg AP1189PlaceboTotal
Female27282782
Male88723
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)50 mg AP1189100 mg AP1189PlaceboTotal
Hispanic or Latino0022
Not Hispanic or Latino353632103
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)50 mg AP1189100 mg AP1189PlaceboTotal
Norway2013
Denmark13151543
Sweden3317
Moldova86721
Bulgaria9121031
08

Study locations

2 sites
  • Aarhus Universitetshospital
    Aarhus, 8200, Denmark
  • Diakonhjemmet Sykehus
    Oslo, 0370, Norway
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Nov 2021, 26 months.

Results were first posted in Jul 2024, 2 years 7 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 26 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Jul 2, 2019
StartActual
Aug 26, 2019
Primary completionActual
Nov 16, 2021
CompletionActual
Nov 16, 2021
Results first posted
Jul 10, 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04004429
Lead sponsor
SynAct Pharma Aps
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Aug 26, 2019
Primary completion
Nov 16, 2021
Completion
Nov 16, 2021
Results posted
Jul 10, 2024
Last update
Jul 10, 2024

Study contacts

Ellen-Margrethe Hauge, Professor
principal investigator · Aarhus University Hospital
Espen A Haavardsholm, Concultant, PhD
principal investigator · Diakonhjemmet Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resomelagon acetate

Start the discussion